Molecular pathological epidemiology gives clues to paradoxical findings

European Journal of Epidemiology

Volumn 30, Issue 10, 2015, Pages 1129-1135

  Nishihara, Reiko ^a,b,c   VanderWeele, Tyler J ^a   Shibuya, Kenji ^c   Mittleman, Murray A ^a,b   Wang, Molin ^a,b   Field, Alison E ^a,b,d,e   Giovannucci, Edward ^a,b   Lochhead, Paul ^f   Ogino, Shuji ^a,b,g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e BROWN UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bias; Cardiovascular disease; Molecular diagnostics; Multifactorial diseases; Personalized medicine

Indexed keywords

SMAD7 PROTEIN;

CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; EPIDEMIOLOGY; GENETIC ASSOCIATION; GLIOBLASTOMA; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY CARCINOMA; MICROENVIRONMENT; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; MOLECULAR PATHOLOGY; MORBIDITY; OBESITY; PROMOTER REGION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA, RENAL CELL; CAUSALITY; COLORECTAL NEOPLASMS; EPIGENETICS; GENETICS; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PUBLIC HEALTH; TRENDS;

CARCINOMA, RENAL CELL; CAUSALITY; COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); EPIDEMIOLOGY; EPIGENOMICS; GLIOBLASTOMA; HUMANS; NEOPLASMS; PATHOLOGY, MOLECULAR; PRECISION MEDICINE; PUBLIC HEALTH; RISK FACTORS;

EID: 84947029052     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-015-0088-4     Document Type: Review

References (84)

1. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156(1):13–22.
2. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666–78.
3. Vemmos K, Ntaios G, Spengos K, et al. Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. Stroke. 2011;42(1):30–6.
4. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82.
5. Ahima RS, Lazar MA. Physiology. The health risk of obesity—better metrics imperative. Science. 2013;341(6148):856–8.
6. Lajous M, Bijon A, Fagherazzi G, et al. Body mass index, diabetes, and mortality in French women: explaining away a “paradox”. Epidemiology. 2014;25(1):10–4.
7. Nguyen US, Niu J, Choi HK, Zhang Y. Commentary: effect of obesity on mortality: comment on article by Banack and Kaufman. Epidemiology. 2014;25(1):2–3.
8. Flanders WD, Eldridge RC, McClellan W. A nearly unavoidable mechanism for collider bias with index-event studies. Epidemiology. 2014;25(5):762–4.
9. Preston SH, Stokes A. Obesity paradox: conditioning on disease enhances biases in estimating the mortality risks of obesity. Epidemiology. 2014;25(3):454–61.
10. Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease? Ann Epidemiol. 2015;25(5):342–9.
11. Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med. 2014;62:96–102.
12. VanderWeele TJ. Commentary: resolutions of the birthweight paradox: competing explanations and analytical insights. Int J Epidemiol. 2014;43(5):1368–73.
13. Ogino S, Giovannucci E. Commentary: lifestyle factors and colorectal cancer microsatellite instability—molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol. 2012;41(4):1072–4.
14. Kuller LH, Bracken MB, Ogino S, Prentice RL, Tracy RP. The role of epidemiology in the era of molecular epidemiology and genomics: summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol. 2013;178(9):1350–4.
15. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5.
16. Ogino S, Nishihara R, VanderWeele TJ, et al. Molecular pathological epidemiology is essential in studying neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. (in press).
17. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26(4):465–84.
18. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102(6):365–7.
19. Wang M, Kuchiba A, Ogino S. A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol. 2015;182(3):263–70.
20. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397–411.
21. Begg CB, Orlow I, Zabor EC, et al. Identifying etiologically distinct sub-types of cancer: a demonstration project involving breast cancer. Cancer Med. 2015;4(9):1432–9.
22. Abbenhardt C, Poole EM, Kulmacz RJ, et al. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet. 2013;4(3):140–9.
23. Amirian ES, Petrosino JF, Ajami NJ, Liu Y, Mims MP, Scheurer ME. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agents Cancer. 2013;8(1):42.
24. Araujo RF Jr, Lira GA, Guedes HG, et al. Lifestyle and family history influence cancer prognosis in Brazilian individuals. Pathol Res Pract. 2013;209(12):753–7.
25. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109(4):1004–12.
26. Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014;20(20):6055–72.
27. Brandstedt J, Wangefjord S, Nodin B, Eberhard J, Jirstrom K, Manjer J. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability. BMC Cancer. 2014;14:371.
28. Coppede F. The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2014;8(8):935–48.
29. Cross AJ, Moore SC, Boca S, et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer. 2014;120(19):3049–57.
30. Hagland HR, Soreide K. Cellular metabolism in colorectal carcinogenesis: influence of lifestyle, gut microbiome and metabolic pathways. Cancer Lett. 2015;356(2 Pt A):273–80.
31. Hoffmeister M, Blaker H, Kloor M, et al. Body mass index and microsatellite instability in colorectal cancer: a population-based study. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2303–11.
32. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 2012;1825(1):77–85.
33. Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One. 2011;6(4):e18571.
34. Hughes LA, Williamson EJ, van Engeland M, et al. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: a pooled analysis. Int J Epidemiol. 2012;41(4):1060–72.
35. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol. 2012;25(8):1055–68.
36. Shaheen NJ. Editorial: what is behind the remarkable increase in esophageal adenocarcinoma? Am J Gastroenterol. 2014;109(3):345–7.
37. Simons CC, van den Brandt PA, Stehouwer CD, van Engeland M, Weijenberg MP. Body size, physical activity, early-life energy restriction, and associations with methylated insulin-like growth factor-binding protein genes in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1852–62.
38. Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52(4):585–9.
39. Zhu Y, Yang SR, Wang PP, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer. 2014;110(5):1359–66.
40. Weisenberger DJ, Levine AJ, Long TI, et al. Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. Cancer Epidemiol Biomarkers Prev. 2015;24(3):512–9.
41. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77–87 e2.
42. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Pathol Res Int. 2011;2011:902674.
43. Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2694–702.
44. Ng JM, Yu J. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci. 2015;16(2):2472–96.
45. Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol. 2015;5:19.
46. Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24(8):1229–38.
47. Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015;64(9):1419–25.
48. Epplein M, Bostick RM, Mu L, Ogino S, Braithwaite D, Kanetsky PA. Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2613–7.
49. Ogino S. Molecular pathological epidemiology (MPE): overview of its paradigm and wide applicability even without tumor tissue [abstract]. In: Proceedings of the twelfth annual AACR international conference on frontiers in cancer prevention research; 2013 Oct 27–30. National Harbor, MD: Cancer Prev Res (Phila); 2013;6:CN06-01.
50. Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015;26(7):959–72.
51. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14(8):16365–85.
52. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13–27.
53. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 2013;5(2):676–713.
54. Lochhead P, Chan AT, Nishihara R, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2015;28(1):14–29.
55. Funkhouser WK Jr, Lubin IM, Monzon FA, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn. 2012;14(2):91–103.
56. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006;98(23):1731–8.
57. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;102(14):1012–22.
58. Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 2013;178(1):84–100.
59. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369(12):1095–105.
60. Brixen LM, Bernstein IT, Bulow S, Ehrnrooth E. Survival of patients with Stage III colon cancer is improved in hereditary non-polyposis colorectal cancer compared with sporadic cases. A Danish registry based study. Colorectal Dis. 2013;15(7):816–23.
61. Levin B. Why hereditary nonpolyposis colorectal carcinoma patients appear to have better survival than patients with sporadic colorectal carcinoma. Cancer. 1998;83(2):201–3.
62. Peters U, Hutter CM, Hsu L, et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet. 2012;131(2):217–34.
63. Phipps AI, Newcomb PA, Garcia-Albeniz X, et al. Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. Gastroenterology. 2012;143(1):51–54 e4.
64. Garcia-Albeniz X, Nan H, Valeri L, et al. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis. 2013;34(2):292–8.
65. Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013;132(3):625–34.
66. Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst. 2013;105(24):1862–70.
67. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–77.
68. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4.
69. McDonald KL, Rapkins RW, Olivier J, et al. The T genotype of the MGMT C > T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. Eur J Cancer. 2013;49(2):360–8.
70. Ogino S, Hazra A, Tranah GJ, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis. 2007;28(9):1985–90.
71. Hawkins NJ, Lee JH, Wong JJ, Kwok CT, Ward RL, Hitchins MP. MGMT methylation is associated primarily with the germline C > T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol. 2009;22(12):1588–99.
72. Gao Q, Tsoi KK, Hirai HW, et al. Serrated polyps and the risk of synchronous colorectal advanced neoplasia: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(4):501–9 (quiz 10).
73. Field AE, Camargo CA Jr, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA. 2013;310(20):2147–8.
74. Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes. JAMA. 2013;310(22):2401–2.
75. van Winkel R. Aetiological stratification as a conceptual framework for gene-by-environment interaction research in psychiatry. Epidemiol Psychiatr Sci. 2015;24(1):6–11.
76. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240–319.
77. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Cancer Netw. 2011;9(Suppl 5):S1–32 (quiz S3).
78. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf). 2013;1(3):166–83.
79. Bayer R, Galea S. Public health in the precision-medicine era. N Engl J Med. 2015;373(6):499–501.
80. Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol. 2012;176(8):659–67.
81. Kuller LH. Invited commentary: the 21st century epidemiologist—a need for different training? Am J Epidemiol. 2012;176(8):668–71.
82. VanderWeele TJ, Knol MJ. Interactions and complexity: goals and limitations. Epidemiol Method. 2014;3(1):79–81.
83. Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut. 2015. doi:10.1136/gutjnl-2014-308852.
84. Ogino S, Beck AH, King EE, Sherman ME, Milner DA, Giovannucci E. Ogino et al. Respond to “The 21st century epidemiologist”. Am J Epidemiol. 2012;176(8):672–4.